myTomorrows, a global platform for pre-approval treatment access, closed a €25 million equity growth funding round led by Avego Healthcare Capital, marking a major step toward improving how patients reach innovative therapies.
“Today marks a huge milestone in our journey,” said the company. “With this investment, and the expertise and network of our new partner, we are ready to build a future where access to all treatments is fair, fast, and truly global.”
Founded by physician and biotech leader Ronald Brus MD, myTomorrows emerged from a personal story of struggling to access experimental treatments. Since inception, the company has evolved from a distribution partner to a comprehensive global access platform that connects patients, physicians, and biopharma companies to pre-approval therapies through AI-powered matching, expanded access management, and real-world data generation.
Headquartered in Amsterdam with offices in New York and an operational hub in India, myTomorrows collaborates with over 60 biopharma companies, supporting more than 16,900 patients, 2,800 physicians, and 340 clinical sites across 134+ countries.
The new funding will be used to expand international operations, enhance AI capabilities, strengthen biopharma partnerships, and scale real-world data solutions. Avego Healthcare Capital Fund II L.P. brings expertise across life sciences and access innovation, reinforcing myTomorrows’ position as a global authority for pre-approval access.
“We believe in a world where every breakthrough has a clear access path to patients in need,” the company stated, highlighting its mission to make early access faster, smarter, and more transparent.
The investment sets the stage for myTomorrows to become the leading global gateway for emerging treatments — bridging innovation, access, and evidence to shape a more connected healthcare future.